Heron Therapeutics, Inc. - Common Stock (HRTX)
0.3706
+0.0776 (26.48%)
NASDAQ · Last Trade: Nov 9th, 5:24 PM EST
News & Press Releases
Heron Therapeutics (NASDAQ:HRTX) Q3 Revenue Misses Estimates as CorMedix Asset Deal Lifts Shareschartmill.com
Via Chartmill · November 9, 2026
Premarket Movers on Nov. 9, 2026: Small-Cap Gainers and Loserschartmill.com
Via Chartmill · November 9, 2026
Heron Therapeutics Announces Third Quarter 2026 Financial Results
CARY, N.C., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2026 and recent corporate updates.
By Heron Therapeutics, Inc. · Via GlobeNewswire · November 9, 2026
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform
By Heron Therapeutics, Inc. · Via GlobeNewswire · November 9, 2026
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
CARY, N.C., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, November 9, 2026, at 8:30 a.m. ET to report third quarter financial results and discuss recent business highlights.
By Heron Therapeutics, Inc. · Via GlobeNewswire · October 26, 2026
Heron Therapeutics Q1 Results Miss, but Acute Care Growth and Reaffirmed Outlook Support HRTXchartmill.com
Via Chartmill · May 11, 2026
Heron Therapeutics Inc (NASDAQ:HRTX) Reports Q4 2025 Revenue Beat and Positive 2026 Outlookchartmill.com
Via Chartmill · February 26, 2026
These stocks are moving in today's after hours sessionchartmill.com
Via Chartmill · September 30, 2026
Get insights into the top gainers and losers of Tuesday's after-hours session.chartmill.com
Via Chartmill · September 1, 2026
Heron (HRTX) Q2 2026 Earnings Call Transcriptfool.com
Patent setback forces guidance withdrawal as acute care revenue surges 44% year over year.
Via The Motley Fool · August 17, 2026
Heron Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
Heron Therapeutics (NASDAQ:HRTX) reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while management said sales of its key products came in below its internal expectations.
Chief Executive Officer C
Via MarketBeat · August 10, 2026
Heron Therapeutics Announces Second Quarter 2026 Financial Results
– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF® net revenue grew 35% and APONVIE® net revenue grew 74% year-over-year
By Heron Therapeutics, Inc. · Via GlobeNewswire · August 10, 2026
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.
By Heron Therapeutics, Inc. · Via GlobeNewswire · July 27, 2026
Keep an eye on the top gainers and losers in Tuesday's session.chartmill.com
Via Chartmill · June 2, 2026
These stocks are moving in today's sessionchartmill.com
Via Chartmill · June 2, 2026
Tuesday's session: gap up and gap down stockschartmill.com
Via Chartmill · June 2, 2026
U.S. District Court Issues Decision Regarding CINVANTI® Patents
After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal
By Heron Therapeutics, Inc. · Via GlobeNewswire · June 2, 2026
Heron (HRTX) Q1 2026 Earnings Call Transcriptfool.com
Heron (HRTX) Q1 2026 Earnings Call Transcript
Via The Motley Fool · May 11, 2026
Which stocks are moving on Monday?chartmill.com
Via Chartmill · May 11, 2026
Heron Therapeutics Q1 Earnings Call Highlightsmarketbeat.com
Heron Therapeutics (NASDAQ:HRTX) said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.
Chief Executive Officer Craig Collard said the company entered 2026 w
Via MarketBeat · May 11, 2026
The market is filled with gapping stocks in Monday's session.chartmill.com
Via Chartmill · May 11, 2026
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.
By Heron Therapeutics, Inc. · Via GlobeNewswire · May 11, 2026
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights.
By Heron Therapeutics, Inc. · Via GlobeNewswire · April 27, 2026
Heron (HRTX) Q4 2025 Earnings Call Transcriptfool.com
Heron (HRTX) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 26, 2026